Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Rigel Pharmaceuticals excels in sales, faces awareness challenges ahead

Rigel Pharmaceuticals demonstrated strong sales performance and efficient cost management in Q4 2022.
The company faces challenges in raising awareness, maintaining persistency, and reaching profitability.
Exploring market opportunities, partnerships, and collaborations position Rigel for future growth.
Competitive trial results and a focus on persistency drive Rigel's competitive edge in the market.

Rigel Pharmaceuticals excels in Q1 with REZLIDHIA and TAVALISSE, faces prescribing behavior challenges

Rigel Pharmaceuticals showcased strong Q1 performance, particularly with REZLIDHIA and TAVALISSE, while facing challenges in understanding prescribing behavior.
The company's focus on differentiated positioning, academic-community growth, and strategic partnerships presents promising opportunities for future expansion.
Financial stability, positive clinician feedback, and ongoing pipeline advancements position Rigel well for continued growth and success in the market.

Rigel Pharmaceuticals reports robust Q2 sales and strategic growth focus

Rigel Pharmaceuticals showcased strong sales performance and product efficacy in Q2, positioning for future growth.
Challenges in managing expenses and strategic decision-making require careful navigation for sustained profitability.
Exploration of new opportunities and continued focus on innovation present avenues for revenue growth and market expansion.
Financial stability, ongoing development programs, and positive market feedback underpin Rigel's strategic direction and growth potential.

Rigel Pharmaceuticals excels in Q3 sales, eyes pipeline expansion

Rigel Pharmaceuticals demonstrated robust sales growth in Q3, managed expenses effectively, and aims for financial breakeven through operational efficiency. The company's strategic focus on pipeline expansion and partnerships positions it well for future growth and innovation.

Rigel Pharmaceuticals posts record sales, eyes growth with Gavreto acquisition

Rigel Pharmaceuticals reported strong financial performance with record sales and net income in Q4 2023.
The acquisition of Gavreto presents growth opportunities in the oncology market.
Challenges include transitioning Gavreto to commercial operations and competition in the targeted therapy space.

Rigel Pharmaceuticals reports strong Q1 performance and growth opportunities

Rigel Pharmaceuticals demonstrated strong performance in Q1 2024 with robust demand for key products and strategic acquisitions.
While facing challenges such as inventory management and financial breakeven, the company is well-positioned for growth.
Opportunities lie in continued sales growth, clinical advancements, and portfolio expansion through in-licensing deals.

Rigel Pharmaceuticals excels in Q2 with strong sales and pipeline progress

Rigel Pharmaceuticals delivered a robust performance in Q2 2024, driven by commercial success, pipeline advancements, and financial discipline. While facing challenges in clinical trial strategies and competitive landscape, the company is well-positioned to capitalize on growth opportunities through product expansions and strategic partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif. , July 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2024 financial results after market close on Tuesday, August 6, 2024.

Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update

Rigel Pharmaceuticals focuses on innovative therapeutics for hematological conditions and cancers, with FDA-approved products Tavalisse, Rezlidhia, and Gavreto targeting specific diseases. RIGL's pipeline also includes promising drug candidates like R289, targeting lower-risk myelodysplastic syndromes and other kinase-related diseases. Gavreto, recently acquired by RIGL, targets RET fusion-positive NSCLC and thyroid cancer, with significant potential for revenue growth.

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

ST. LOUIS--(BUSINESS WIRE)--Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces a contractual partnership with Rigel Pharmaceuticals, Inc., effective July 1, 2024, bringing its comprehensive suite of services to support patients using GAVRETO® (pralsetinib). GAVRETO® is a targeted therapy that is taken by mouth once daily and is used to treat certain cancers caused by abnormal RET genes. Optime Care's offerings for life sciences manufacturers en.

Optime Care Announces Enhanced Partnership with Rigel Pharmaceuticals for GAVRETO® Patients

SOUTH SAN FRANCISCO, Calif. , June 25, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will effect a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10 (the "Reverse Stock Split"), effective at 12:01 a.m.

Rigel Announces Reverse Stock Split

GAVRETO will be available from Rigel in the U.S. beginning June 27, 2024 SOUTH SAN FRANCISCO, Calif. , June 24, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced the completion of the transfer to Rigel of the New Drug Application (NDA) for GAVRETO® (pralsetinib) for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by a U.S. Food and Drug Administration (FDA) approved test and adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application

Eledon Pharmaceuticals

Tilray Brands

Penny stocks sometimes get a bad rep due to their inherent risk. They are cheap but are considered highly volatile and have a low chance of providing substantial profit.

Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues

-     Oral presentation highlighting final five-year efficacy data from the registrational Phase 2 trial of REZLIDHIA® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML , including those receiving prior venetoclax -     New data shows clinically meaningful effect of olutasidenib in patients with mIDH1 AML secondary to MPN and as bridge-to-transplant treatment in patients with R/R mIDH1 AML SOUTH SAN FRANCISCO, Calif. , June 14, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced one oral and four poster presentations at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain being held June 13-16, 2024, and online.

Rigel Announces Five Presentations at the EHA2024 Hybrid Congress

-       Long-term efficacy data from the registrational Phase 2 trial of REZLIDHIA ®  (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML, including those receiving prior venetoclax -       Data from a subgroup analyses of elderly R/R mIDH1 AML patients treated with olutasidenib shows consistent CR/CRh results -       Overview of the Phase 1b trial  of R289 in patients with lower-risk MDS SOUTH SAN FRANCISCO, Calif. , June 3, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the presentation of three posters at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL today and online.

Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting

SOUTH SAN FRANCISCO, Calif. , May 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:30 am ET in New York, NY.

Rigel to Present at the Jefferies Global Healthcare Conference

Oral presentation of f inal five-year results from the registrational Phase 2 trial in R/R mIDH1 AML patients reinforces REZLIDHIA® (olutasidenib) efficacy in heavily pretreated patients, including those receiving prior venetoclax Other key posters further support the efficacy of REZLIDHIA ® (olutasidenib) in elderly, transplant-eligible, and post-MPN patients with AML SOUTH SAN FRANCISCO, Calif. , May 23, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced upcoming presentations from their commercial and clinical-stage hematology and oncology portfolio at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2024 Hybrid Congress.

Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

Rigel (RIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Rigel (RIGL) Upgraded to Buy: Here's What You Should Know

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel and Corporate Secretary Raul Rodriguez - President and Chief Executive Officer Dave Santos - Chief Commercial Officer Lisa Rojkjaer - Chief Medical Officer Dean Schorno - Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citigroup Kristen Kluska - Cantor Fitzgerald Farzin Haque - Jefferies Operator Greetings and welcome to Rigel Pharmaceuticals Financial Conference Call for the First Quarter 2024. At this time, all participants are in a listen-only mode.

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2024 Earnings Call Transcript

Rigel Pharmaceuticals (RIGL) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.08 per share a year ago.

Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Lags Revenue Estimates

First quarter 2024 total revenue of $29.5 million, which includes TAVALISSE® net product sales of $21.1 million and REZLIDHIA ®  net product sales of $4.9 million Expanded Rigel's portfolio with acquisition of GAVRETO®, a U.S. marketed product for RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer Appointed Lisa Rojkjaer, M.D. as Chief Medical Officer Conference call and webcast scheduled today at 4:30 p.m.

Rigel Reports First Quarter 2024 Financial Results and Provides Business Update

Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rigel Pharmaceuticals (RIGL) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

SOUTH SAN FRANCISCO, Calif. , April 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2024 financial results after market close on Tuesday, May 7, 2024.

Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update

Rigel Pharmaceuticals has multiple approved agents and a modest pipeline of developmental projects. The company has a stable financial position with growing sales and a new product in its stable. Rigel Pharmaceuticals faces both strengths and risks in the competitive pharmaceutical industry.

Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy

Olutasidenib induced durable composite complete remission in 43.8% of patients relapsed or refractory to prior venetoclax-based regimens Safety was consistent with the overall profile of olutasidenib Olutasidenib may offer a valuable treatment option for patients with mIDH1 previously treated with venetoclax SOUTH SAN FRANCISCO, Calif. , April 4, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication in Leukemia & Lymphoma on data from an analysis of the Phase 2 study evaluating REZLIDHIA® (olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1)1, in patients with mIDH1 acute myeloid leukemia (AML) who were relapsed/refractory (R/R) to prior venetoclax-based regimens.

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma

SOUTH SAN FRANCISCO, Calif. , March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D.

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q4 2023 Earnings Conference Call March 5, 2024 4:30 AM ET Company Participants Ray Furey - Executive Vice President, General Counsel and Corporate Secretary Raul Rodriguez - President and Chief Executive Officer Dave Santos - Chief Commercial Officer Francois Di Trapani - Senior Vice President of Medical Affairs Dean Schorno - Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citigroup Kristen Kluska - Cantor Fitzgerald Kalpit Patel - B. Riley Securities Operator Greetings and welcome to Rigel Pharmaceuticals Financial Conference Call for the Fourth Quarter and Full Year 2023.

Rigel Pharmaceuticals, Inc. (RIGL) Q4 2023 Earnings Call Transcript

Rigel Pharmaceuticals (RIGL) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.01 per share a year ago.

Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4

Fourth quarter 2023 Total Revenue of $35.8 million which includes TAVALISSE® net product sales of $25.7 million and REZLIDHIA ® net product sales of $3.9 million Expanded product portfolio with acquisition of U.S. rights to GAVRETO®, an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.

Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2023 financial results after market close on Tuesday, March 5, 2024.

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update

Rigel Pharmaceuticals has acquired the U.S. rights to GAVRETO, an FDA-approved drug for certain types of lung and thyroid cancer. GAVRETO has the potential to boost Rigel's earnings immediately and position the company strategically in the precision oncology market. Rigel's acquisition of GAVRETO faces competition from Eli Lilly's RET kinase inhibitor, but GAVRETO has advantages in terms of efficacy and safety.

Rigel Pharmaceuticals: Gavreto Deal Expands Growth Prospects

Rigel Pharmaceuticals reported promising preliminary Q4 and full-year 2023 results, with record-breaking net product sales for TAVALISSE and REZLIDHIA. The company's cash position remains healthy, providing support for its corporate, commercial, and pipeline initiatives. Investors should look out for updates on commercial information, efforts to expand olutasidenib, and the development of other products beyond TAVALISSE and REZLIDHIA.

News for Rigel Pharmaceuticals Stock (RIGL)